An. Fac. med.   2003; 64 (2):  89 - 93 

 

TRATAMIENTO DE STRONGYLOIDES STERCORALIS  CON IVERMECTINA Y TIABENDAZOLE 

 

BIBLIOGRAFÍA


1. Vildósola, G. Estrongiloidiasis. Rev Gastroenterol Perú 1997; 17, Supl 1: S75-S91.

2. Huapaya P, Chávez V, Valverde S, Rose M. Prevalencia de Strongyloidiasis en lactantes y pre-escolares de la Provincia de Chanchamayo. Bol Peruano Parasitol 1995; 11: 32-4. 

3. Hernández F. Strongyloides stercoralis: un parásito subestimado. Parasitología al Día 2001; 25: 40-9.

4. Liñan-Abanto R, Jara C. Frecuencia y aspectos epidemiológicos del parasitismo por helmintos intestinales en la población infantil de Paiján, La Libertad-Perú. Bol Peruano Parasitol 1995; 11: 46-50.

5. Vásquez E, Gamero F, Aguirre E. Enteroparasitosis en el asentamiento humano Enrique Milla Ochoa - Los Olivos. Bol Peruano Parasitol 1995; 11: 55-6.

6. Tantaleán M, Atencia G. Nota sobre parasitismo intestinal diagnosticado en el IMT Daniel A. Carrión. Rev Per Med Trop UNMSM 1993; 7(2): 99-103.

7. Bannon J, Fater M. Intestinal ileus secondary to Strongyloides stercoralis infection: case report and review of the literature. Am Surgeon 1995; 61(4): 377-41.

8. Boyd W, Campbell F, Trudeau W. Strongyloides stercoralis - Hyperinfection. Am J Trop Med Hyg 1978; 27(1): 39-41.

9. Gotuzzo E, Terashima A, Alvarez H, Tello R, Infante R, Watts D, Freedman D. Strongyloides stercoralis hyperinfection associated with human T cell lymphotropic virus type - 1 in Peru. Am J Trop Med Hyg 1999; 60(1): 146-9.

10. Goyal S. Intestinal strongyloidiasis manifesting as eosinophilic pleural effusion. Southern Med J 1998; 91 (8): 768-70.

11. Herrera J, Herrera J. Estrongiloidiasis: Presentación quirúrgica de dos casos en el Hospital Central SSPNP - 1988. Rev Sanidad Policía Nac 1989; 50(2): 110-8.

12. Marchesan M, Cardoso R, Anefalos A, Kobayasi S. Invasive enteritis by Strongyloides stercoralis presenting as acute abdominal distress under corticosteroid therapy. Rev Hosp Clín Fac Med Sao Paulo 2001; 56 (4): 103-6.

13. Neva F. Biology and immunology of human strongyloidiasis. J Infect Dis 1986; 154(3): 397- 406. 

14. Nonaka D, Takaki K, Tanaka M, Umeno M, Takeda T, Yoshida M, et al. Paralitic ileus due to Strongyloidiasis: case report and review of the literature. Am J Trop Med Hyg 1998; 59(4): 535-8. 

15. Shelhamer J, Neva F, Finn D. Persistent Strongyloidiasis in an immunodeficient patient. Am J Trop Med Hyg 1982; 31(4): 746-51.

16. Terashima A, Gotuzzo E, Alvarez H, Infante R, Tello R, Watts D, Freedman D. Strongyloides stercoralis: Formas clínicas severas asociadas a infección por HTLV-I. Rev Gastroenterol Perú 1999; 19(1): 35-40.

17. Datry A, Hilmarsdottir I, Mayorga R, Lyagoubi M, Gaxotte P, Biligui S, et al. Treatment of Strongyloides stercoralis infections with ivermectin compared with albendazol: results of an open study of 60 cases. Transact Royal Soc Trop Med Hyg 1994; 88: 344-5.

18. Gann P, Neva F, Gam A. A randomized trial of single and two dose ivermectin versus thiabendazole for treatment of Strongyloidiasis. J Infect Dis 1994; 169: 1076-9.

19. Lindo J, Atkins N, Lee M, Robinson R, Bundy D. Parasite-specific serum IgG following successful treatment of endemic strongyloidiasis using ivermectin. Transact Royal Soc Trop Med Hyg 1996; 90: 702-3.

20. Náquira C, Jimenez G, Guerra J, Bernal R, Nalin D, Neu D, Aziz M. Ivermectin for human strongyloidiasis and other intestinal helminths. Am J Trop Med Hyg 1989; 40(3): 304-9.

21. Shikiya K, Kinjo N, Uehara T, Uechi H, Ohshiro J, Arakaki T, et al. Efficacy of ivermectin against Strongyloides stercoralis in humans. Internal Med 1993; 31(3): 310-2.

22. Most H, Yoeli M, Campbell W, Cuckler A. The treatment of Strongyloides and Enterobius infections with thiabendazole. Am J Trop Med Hyg 1965; 14(3): 379-82.

23. Cahill K. Thiabendazol in massive strongyloidiasis. Am J Trop Med Hyg 1967; 16(4): 451-3.

24. Franz K, Schneider, Pohlman M. Clinical trials with thiabendazole against intestinal nematodes infecting humans. Am J Trop Med Hyg 1965; 14(3): 383-6.

25. Grove D. Treatment of strongyloidiasis with thiabendazole: an analysis of toxicity and effectiveness. Transact Royal Soc Trop Med Hyg 1982; 76(1): 114-8.

26. Portugal R, Schaffel R, Almeida L, Spector N, Nucci M. Thiabendazole for the prophylaxis of strongyloidiasis in immunosuppressed patients with hematological diseases: a randomized double-blind placebo-controlled study. Haematol 2002; 87(6): 663-4. 

27. Eland IA, Kerkhof SC, Overbosch D, Wismans PJ, Stricker BH. Cholestatic hepatitis ascribed to the use of thiabendazole. Ned Tijdschr Geneeskd 1998; 142(23): 1331-4. 

28. Marron Gasca J, Gimenez Serrano H, Calvo Morales A, Pastor Bajo JA, Aizpun Pon M. Fixed exanthema induced by thiabendazole. Actas Dermosifiliogr 1976; 67(9-10): 701-6. 

29. Tada Y, Fujitani T, Yano N, Yuzawa K, Nagasawa A, Aoki N, et al. Chronic toxicity of thiabendazole (TBZ) in CD-1 mice. Toxicol 2001; 169(3): 163-76.

30. Terashima A, Alvarez H, Tello R, Infante R, Freedman DO, Gotuzzo E. Treatment failure in intestinal Strongyloidiasis: an indicator of HTLV-1 infection. Int J Infect Dis 2002; 6(1): 28-30.

31. Davidson, R, Fletcher R, Chapman L. Risk factors for Strongyloidiasis. A case-control study. Arch Intern Med 1984; 144: 321-4.

32. Godoy P, Camargos C, Costa G, Fonseca L. Associação timoma e strongiloidíase intestinal grave. Rev Soc Brasileira Med Trop 1998; 31(5): 481-5.

33. Maciel E, Espinheira L, Brites C. Strongyloidiasis as an opportunistic infection in a HAM/TSP patient. Brazilian J Infect Dis 1999; 3(1): 23-7.


Regresar

 


back.gif (71 bytes) Contenido

Volumenes anteriores

Revistas